Switch theme
Sign up to access all valuation multiples
S2Medical AB is a research-intensive MedTech company from Sweden. The company has developed several unique wound care products and has many disruptive technologies in the pipeline. Its products include wound debridment, blood stilling, skin grafting, tissue substitutes, bandage, and antimicrobial.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
S2Medical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, S2Medical achieved revenue of $1.5M and an EBITDA of $0.7M.
S2Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See S2Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.7M | $1.5M | XXX | XXX | XXX |
| Gross Profit | $0.5M | $0.5M | XXX | XXX | XXX |
| Gross Margin | 74% | 34% | XXX | XXX | XXX |
| EBITDA | -$1.4M | $0.7M | XXX | XXX | XXX |
| EBITDA Margin | -194% | 46% | XXX | XXX | XXX |
| Net Profit | -$3.0M | -$2.3M | XXX | XXX | XXX |
| Net Margin | -423% | -152% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, S2Medical's stock price is SEK 0 (or $0).
S2Medical has current market cap of SEK 10.6M (or $1.1M), and EV of SEK 9.6M (or $1.0M).
See S2Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0M | $1.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, S2Medical has market cap of $1.1M and EV of $1.0M.
S2Medical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate S2Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for S2Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 1.4x | XXX | XXX | XXX |
| P/E | 1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialS2Medical's NTM/LTM revenue growth is n/a
S2Medical's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged n/a for the same period.
Over next 12 months, S2Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate S2Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for S2Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 114% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -150% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
S2Medical acquired XXX companies to date.
Last acquisition by S2Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . S2Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was S2Medical founded? | S2Medical was founded in 2013. |
| Where is S2Medical headquartered? | S2Medical is headquartered in Sweden. |
| How many employees does S2Medical have? | As of today, S2Medical has 17 employees. |
| Is S2Medical publicy listed? | Yes, S2Medical is a public company listed on STO. |
| What is the stock symbol of S2Medical? | S2Medical trades under S2M ticker. |
| When did S2Medical go public? | S2Medical went public in 2018. |
| Who are competitors of S2Medical? | Similar companies to S2Medical include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of S2Medical? | S2Medical's current market cap is $1.1M |
| What is the current revenue growth of S2Medical? | S2Medical revenue growth between 2023 and 2024 was 114%. |
| Is S2Medical profitable? | Yes, S2Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
